Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Prostate Cancer

  Free Subscription


Articles published in J Clin Oncol

Retrieve available abstracts of 116 articles:
HTML format



Single Articles


    September 2020
  1. KYRIAKOPOULOS CE, Heath EI, Ferrari A, Sperger JM, et al
    Exploring Spatial-Temporal Changes in (18)F-Sodium Fluoride PET/CT and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide.
    J Clin Oncol. 2020 Sep 8:JCO2000348. doi: 10.1200/JCO.20.00348.
    PubMed     Abstract available


  2. SCHWEIZER MT, Cheng HH, Nelson PS, Montgomery RB, et al
    Two Steps Forward and One Step Back for Precision in Prostate Cancer Treatment.
    J Clin Oncol. 2020 Sep 8:JCO2001755. doi: 10.1200/JCO.20.01755.
    PubMed    


  3. MARKOWSKI MC, Antonarakis ES
    BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?
    J Clin Oncol. 2020 Sep 1:JCO2002246. doi: 10.1200/JCO.20.02246.
    PubMed    


    August 2020
  4. ABIDA W, Patnaik A, Campbell D, Shapiro J, et al
    Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
    J Clin Oncol. 2020 Aug 14:JCO2001035. doi: 10.1200/JCO.20.01035.
    PubMed     Abstract available


    July 2020
  5. EASTHAM JA, Heller G, Halabi S, Monk JP 3rd, et al
    Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
    J Clin Oncol. 2020 Jul 24:JCO2000315. doi: 10.1200/JCO.20.00315.
    PubMed     Abstract available


    June 2020
  6. XIE W, Regan MM, Buyse M, Halabi S, et al
    Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
    J Clin Oncol. 2020 Jun 18:JCO1903114. doi: 10.1200/JCO.19.03114.
    PubMed     Abstract available


  7. GIRI VN, Knudsen KE, Kelly WK, Cheng HH, et al
    Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
    J Clin Oncol. 2020 Jun 9:JCO2000046. doi: 10.1200/JCO.20.00046.
    PubMed     Abstract available


    May 2020
  8. JACKSON WC, Hartman HE, Dess RT, Birer SR, et al
    Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials.
    J Clin Oncol. 2020 May 12:JCO1903217. doi: 10.1200/JCO.19.03217.
    PubMed     Abstract available


  9. MARSHALL CH, Joshu CE
    Mounting Weight of Evidence on the Importance of Body Weight for Men With Prostate Cancer.
    J Clin Oncol. 2020 May 5:JCO2000791. doi: 10.1200/JCO.20.00791.
    PubMed    


    April 2020
  10. TROESCHEL AN, Hartman TJ, Jacobs EJ, Stevens VL, et al
    Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer.
    J Clin Oncol. 2020 Apr 6:JCO1902185. doi: 10.1200/JCO.19.02185.
    PubMed     Abstract available


    March 2020
  11. GHADJAR P, Bohmer D, Hocht S, Sedlmayer F, et al
    Need for Androgen Deprivation Therapy in Addition to Definitive Radiation Therapy in Patients With Intermediate-Risk Localized Prostate Cancer.
    J Clin Oncol. 2020 Mar 25:JCO2000149. doi: 10.1200/JCO.20.00149.
    PubMed    


  12. BEEBE-DIMMER JL, Kapron AL, Fraser AM, Smith KR, et al
    Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
    J Clin Oncol. 2020 Mar 24:JCO1902808. doi: 10.1200/JCO.19.02808.
    PubMed     Abstract available


  13. AVKSHTOL V, Ruth KJ, Ross EA, Hallman MA, et al
    Ten-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer.
    J Clin Oncol. 2020 Mar 2:JCO1901485. doi: 10.1200/JCO.19.01485.
    PubMed     Abstract available


    February 2020
  14. AGOCHUKWU NQ, Wittmann D, Boileau NR, Dunn RL, et al
    Reply to K.P. Weinfurt et al.
    J Clin Oncol. 2020;38:654-655.
    PubMed    


  15. VICKERS AJ
    Reply to K.P. Weinfurt et al.
    J Clin Oncol. 2020;38:653-654.
    PubMed    


    January 2020
  16. SAYLOR PJ, Rumble RB, Tagawa S, Eastham JA, et al
    Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline.
    J Clin Oncol. 2020 Jan 28:JCO1903148. doi: 10.1200/JCO.19.03148.
    PubMed     Abstract available


  17. TRABULSI EJ, Rumble RB, Jadvar H, Hope T, et al
    Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline.
    J Clin Oncol. 2020 Jan 15:JCO1902757. doi: 10.1200/JCO.19.02757.
    PubMed     Abstract available


  18. NOSSITER J, Sujenthiran A, Cowling TE, Parry MG, et al
    Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England.
    J Clin Oncol. 2020 Jan 2:JCO1901538. doi: 10.1200/JCO.19.01538.
    PubMed     Abstract available


    December 2019
  19. SLOVIN SF
    Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer: Can an Agnostic Become a Believer?
    J Clin Oncol. 2019 Dec 26:JCO1902921. doi: 10.1200/JCO.19.02921.
    PubMed    


  20. MALONE S, Roy S, Eapen L, E C, et al
    Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial.
    J Clin Oncol. 2019 Dec 12:JCO1901904. doi: 10.1200/JCO.19.01904.
    PubMed     Abstract available


  21. EGGENER SE, Rumble RB, Armstrong AJ, Morgan TM, et al
    Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.
    J Clin Oncol. 2019 Dec 12:JCO1902768. doi: 10.1200/JCO.19.02768.
    PubMed     Abstract available


    November 2019
  22. ANTONARAKIS ES, Piulats JM, Gross-Goupil M, Goh J, et al
    Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
    J Clin Oncol. 2019 Nov 27:JCO1901638. doi: 10.1200/JCO.19.01638.
    PubMed     Abstract available


  23. DANILA DC, Szmulewitz RZ, Vaishampayan U, Higano CS, et al
    Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2019 Nov 5:JCO1900646. doi: 10.1200/JCO.19.00646.
    PubMed     Abstract available


    October 2019
  24. MCNEEL DG, Eickhoff JC, Johnson LE, Roth AR, et al
    Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer.
    J Clin Oncol. 2019 Oct 23:JCO1901701. doi: 10.1200/JCO.19.01701.
    PubMed     Abstract available


    September 2019
  25. VICKERS A, Carlsson SV
    Toward Responsible, Informed Decision Making for Prostate Cancer Treatment Decisions.
    J Clin Oncol. 2019 Sep 30:JCO1900989. doi: 10.1200/JCO.19.00989.
    PubMed    


  26. VANDERWEELE DJ, Antonarakis ES, Carducci MA, Dreicer R, et al
    Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy.
    J Clin Oncol. 2019 Sep 10:JCO1901595. doi: 10.1200/JCO.19.01595.
    PubMed    


  27. PALLER CJ, Eisenberger MA
    Progress in the Systemic Management of Advanced Prostate Cancer: The Hormone-Sensitive Paradigm.
    J Clin Oncol. 2019 Sep 4:JCO1901863. doi: 10.1200/JCO.19.01863.
    PubMed    


    July 2019
  28. ARMSTRONG AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al
    ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
    J Clin Oncol. 2019 Jul 22:JCO1900799. doi: 10.1200/JCO.19.00799.
    PubMed     Abstract available


  29. SHARP A, Porta N, Lambros MBK, Welti JC, et al
    Dissecting Prognostic From Predictive Utility: Circulating AR-V7 Biomarker Testing for Advanced Prostate Cancer.
    J Clin Oncol. 2019 Jul 2:JCO1901104. doi: 10.1200/JCO.19.01104.
    PubMed    


  30. DIRIX L
    Predictive Significance of Androgen Receptor Splice Variant 7 in Patients With Metastatic Castration-Resistant Prostate Cancer: The PROPHECY Study.
    J Clin Oncol. 2019 Jul 2:JCO1900811. doi: 10.1200/JCO.19.00811.
    PubMed    


  31. ARAGON-CHING JB
    Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?
    J Clin Oncol. 2019 Jul 1:JCO1900977. doi: 10.1200/JCO.19.00977.
    PubMed    


    April 2019
  32. DOWNER MK, Kenfield SA, Stampfer MJ, Wilson KM, et al
    Alcohol Intake and Risk of Lethal Prostate Cancer in the Health Professionals Follow-Up Study.
    J Clin Oncol. 2019 Apr 26:JCO1802462. doi: 10.1200/JCO.18.02462.
    PubMed     Abstract available


  33. GIRI VN, Hyatt C, Gomella LG
    Germline Testing for Men With Prostate Cancer: Navigating an Expanding New World of Genetic Evaluation for Precision Therapy and Precision Management.
    J Clin Oncol. 2019 Apr 12:JCO1802181. doi: 10.1200/JCO.18.02181.
    PubMed    


  34. MCKAY RR, Ye H, Xie W, Lis R, et al
    Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
    J Clin Oncol. 2019;37:923-931.
    PubMed     Abstract available


    March 2019
  35. SKOLARUS TA, Metreger T, Wittmann D, Hwang S, et al
    Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial.
    J Clin Oncol. 2019 Mar 29:JCO1801770. doi: 10.1200/JCO.18.01770.
    PubMed     Abstract available


  36. PARIKH RR, Saraiya B
    Multidisciplinary Care in High-Risk Prostate Cancer Is the New Standard of Care.
    J Clin Oncol. 2019 Mar 22:JCO1900298. doi: 10.1200/JCO.19.00298.
    PubMed    


  37. ARMSTRONG AJ, Halabi S, Luo J, Nanus DM, et al
    Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
    J Clin Oncol. 2019 Mar 13:JCO1801731. doi: 10.1200/JCO.18.01731.
    PubMed     Abstract available


  38. ROSENTHAL SA, Hu C, Sartor O, Gomella LG, et al
    Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.
    J Clin Oncol. 2019 Mar 12:JCO1802158. doi: 10.1200/JCO.18.02158.
    PubMed     Abstract available


  39. JAYADEVAPPA R, Chhatre S, Gallo JJ, Wittink M, et al
    Patient-Centered Preference Assessment to Improve Satisfaction With Care Among Patients With Localized Prostate Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2019 Mar 12:JCO1801091. doi: 10.1200/JCO.18.01091.
    PubMed     Abstract available


    February 2019
  40. GULLEY JL, Borre M, Vogelzang NJ, Ng S, et al
    Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2019 Feb 28:JCO1802031. doi: 10.1200/JCO.18.02031.
    PubMed     Abstract available


  41. VAPIWALA N, Hofman MS, Murphy DG, Williams S, et al
    Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart.
    J Clin Oncol. 2019 Feb 22:JCO1801927. doi: 10.1200/JCO.18.01927.
    PubMed    


  42. MARTIN J, Lukka H, Catton C
    Reply to J. David et al.
    J Clin Oncol. 2019;37:441.
    PubMed    


  43. VOLTA AD, Cosentini D, Antonelli A, Pedersini R, et al
    Transformation of Prostate Adenocarcinoma Into Small-Cell Neuroendocrine Cancer Under Androgen Deprivation Therapy: Much Is Achieved But More Information Is Needed.
    J Clin Oncol. 2019;37:350-351.
    PubMed    


  44. AGGARWAL R, Huang J, Alumkal J, Feng FY, et al
    Reply to A. Dalla Volta et al.
    J Clin Oncol. 2019;37:351-352.
    PubMed    


    January 2019
  45. CASTRO E, Romero-Laorden N, Del Pozo A, Lozano R, et al
    PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2019 Jan 9:JCO1800358. doi: 10.1200/JCO.18.00358.
    PubMed     Abstract available


  46. BERMAN E, Druker BJ, Burwick R
    Reply to N. Cerveira et al.
    J Clin Oncol. 2019;37:90-91.
    PubMed    


    December 2018
  47. DAVID J, Kamrava M
    Prostate Cancer Radiotherapy: An Evolving Paradigm That Should Also Include High-Dose-Rate Monotherapy.
    J Clin Oncol. 2018 Dec 28:JCO1801482. doi: 10.1200/JCO.18.01482.
    PubMed    


  48. HALABI S, Dutta S, Tangen CM, Rosenthal M, et al
    Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
    J Clin Oncol. 2018 Dec 21:JCO1801279. doi: 10.1200/JCO.18.01279.
    PubMed     Abstract available


  49. PARIKH RB, Prasad V
    Metastasis-Free Survival in Prostate Cancer: Faster Drug Approvals, Better Drugs?
    J Clin Oncol. 2018 Dec 11:JCO1801092. doi: 10.1200/JCO.18.01092.
    PubMed    


  50. DIGNAM JJ, Hamstra DA, Lepor H, Grignon D, et al
    Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202.
    J Clin Oncol. 2018 Dec 7:JCO1800154. doi: 10.1200/JCO.18.00154.
    PubMed     Abstract available


    October 2018
  51. MORGAN SC, Hoffman K, Loblaw DA, Buyyounouski MK, et al
    Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline.
    J Clin Oncol. 2018 Oct 11:JCO1801097. doi: 10.1200/JCO.18.01097.
    PubMed    


    September 2018
  52. GOMEZ-ITURRIAGA A, Crook J
    High-Risk Localized Prostate Cancer: How Important Is the Addition of Brachytherapy to External-Beam Radiotherapy?
    J Clin Oncol. 2018 Sep 13:JCO1800704. doi: 10.1200/JCO.18.00704.
    PubMed    


  53. VELHO PI, Eisenberger MA
    There Is Now Compelling Evidence to Further Evaluate Lower Doses of Abiraterone Acetate in Men With Metastatic Prostate Cancer: It Should Be Safer, May Be as Effective and Less Expensive.
    J Clin Oncol. 2018 Sep 6:JCO2018793166. doi: 10.1200/JCO.2018.79.3166.
    PubMed    


  54. BEKELMAN JE, Rumble RB, Chen RC, Pisansky TM, et al
    Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.
    J Clin Oncol. 2018 Sep 5:JCO1800606. doi: 10.1200/JCO.18.00606.
    PubMed     Abstract available


    August 2018
  55. CATTON CN, Lukka H, Martin J
    Prostate Cancer Radiotherapy: An Evolving Paradigm.
    J Clin Oncol. 2018 Aug 23:JCO2018793257. doi: 10.1200/JCO.2018.79.3257.
    PubMed     Abstract available


  56. HOFFMAN KE, Voong KR, Levy LB, Allen PK, et al
    Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer.
    J Clin Oncol. 2018 Aug 14:JCO2018779868. doi: 10.1200/JCO.2018.77.9868.
    PubMed     Abstract available


    July 2018
  57. ATTARD G, Borre M, Gurney H, Loriot Y, et al
    Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.
    J Clin Oncol. 2018 Jul 20:JCO2018779827. doi: 10.1200/JCO.2018.77.9827.
    PubMed     Abstract available


  58. AGGARWAL R, Huang J, Alumkal JJ, Zhang L, et al
    Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study.
    J Clin Oncol. 2018 Jul 9:JCO2017776880. doi: 10.1200/JCO.2017.77.6880.
    PubMed     Abstract available


    June 2018
  59. REN C, Han C, Wang D, Chen H, et al
    Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen?
    J Clin Oncol. 2018 Jun 12:JCO2018781401. doi: 10.1200/JCO.2018.78.1401.
    PubMed    


  60. BIBAULT JE, Blanchard P
    Treating Metastatic Prostate Cancer With Local Therapies: Is It Still Wishful Thinking?
    J Clin Oncol. 2018 Jun 1:JCO2017775429. doi: 10.1200/JCO.2017.77.5429.
    PubMed    


  61. CATTRINI C, Zanardi E, Boccardo F
    Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer.
    J Clin Oncol. 2018 Jun 1:JCO2018780031. doi: 10.1200/JCO.2018.78.0031.
    PubMed    


    May 2018
  62. SPRATT DE, Carroll PR
    Optimal Radical Therapy for Localized Prostate Cancer: Recreation of the Self-Fulfilling Prophecy With Combination Brachytherapy?
    J Clin Oncol. 2018 May 21:JCO2018786236. doi: 10.1200/JCO.2018.78.6236.
    PubMed    


  63. BEKELMAN JE
    A Younger Man With Localized Prostate Cancer Asks, "Which Type of Radiation Is Right for Me?"
    J Clin Oncol. 2018 May 2:JCO2018777235. doi: 10.1200/JCO.2018.77.7235.
    PubMed     Abstract available


    April 2018
  64. JANSSON F, Drevin L, Frisell T, Stattin P, et al
    Concordance of Non-Low-Risk Disease Among Pairs of Brothers With Prostate Cancer.
    J Clin Oncol. 2018 Apr 13:JCO2017766907. doi: 10.1200/JCO.2017.76.6907.
    PubMed     Abstract available


  65. SARTOR O
    Curing More Prostate Cancer: Thinking Through the Options.
    J Clin Oncol. 2018 Apr 6:JCO2018784835. doi: 10.1200/JCO.2018.78.4835.
    PubMed    


  66. HUSSAIN M, Tangen CM, Thompson IM Jr, Swanson GP, et al
    Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
    J Clin Oncol. 2018 Apr 6:JCO2017764126. doi: 10.1200/JCO.2017.76.4126.
    PubMed     Abstract available


  67. MORRIS MJ, Rumble RB, Basch E, Hotte SJ, et al
    Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    J Clin Oncol. 2018 Apr 2:JCO2018780619. doi: 10.1200/JCO.2018.78.0619.
    PubMed     Abstract available


    March 2018
  68. SZMULEWITZ RZ, Peer CJ, Ibraheem A, Martinez E, et al
    Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2018 Mar 28:JCO2017764381. doi: 10.1200/JCO.2017.76.4381.
    PubMed     Abstract available


  69. PAN HY, Jiang J, Hoffman KE, Tang C, et al
    Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.
    J Clin Oncol. 2018 Mar 21:JCO2017755371. doi: 10.1200/JCO.2017.75.5371.
    PubMed     Abstract available


  70. MORGANS AK, Chen YH, Sweeney CJ, Jarrard DF, et al
    Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
    J Clin Oncol. 2018 Mar 9:JCO2017753335. doi: 10.1200/JCO.2017.75.3335.
    PubMed     Abstract available


    February 2018
  71. ENNIS RD, Hu L, Ryemon SN, Lin J, et al
    Brachytherapy-Based Radiotherapy and Radical Prostatectomy Are Associated With Similar Survival in High-Risk Localized Prostate Cancer.
    J Clin Oncol. 2018 Feb 28:JCO2017759134. doi: 10.1200/JCO.2017.75.9134.
    PubMed     Abstract available


  72. CHEN RC
    Challenges of Interpreting Registry Data in Prostate Cancer: Interpreting Retrospective Results Along With or in Absence of Clinical Trial Data.
    J Clin Oncol. 2018 Feb 28:JCO2017775833. doi: 10.1200/JCO.2017.77.5833.
    PubMed    


  73. TSAO CK, Oh WK
    First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care?
    J Clin Oncol. 2018 Feb 12:JCO2017774315. doi: 10.1200/JCO.2017.77.4315.
    PubMed    


  74. FAIENA I, Holden S, Cooperberg MR, Holden S, et al
    Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?
    J Clin Oncol. 2018 Feb 5:JCO2017764050. doi: 10.1200/JCO.2017.76.4050.
    PubMed    


    January 2018
  75. KYRIAKOPOULOS CE, Chen YH, Carducci MA, Liu G, et al
    Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
    J Clin Oncol. 2018 Jan 31:JCO2017753657. doi: 10.1200/JCO.2017.75.3657.
    PubMed     Abstract available


  76. HORIGUCHI M, Uno H, Wei LJ
    Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer.
    J Clin Oncol. 2018 Jan 26:JCO2017759829. doi: 10.1200/JCO.2017.75.9829.
    PubMed    


  77. ABIDA W, Sawyers CL
    Targeting DNA Repair in Prostate Cancer.
    J Clin Oncol. 2018 Jan 25:JCO2017766592. doi: 10.1200/JCO.2017.76.6592.
    PubMed    


  78. MORGANS AK
    Optimization of Risk Stratification in Localized Prostate Cancer.
    J Clin Oncol. 2018 Jan 5:JCO2017762971. doi: 10.1200/JCO.2017.76.2971.
    PubMed     Abstract available


    December 2017
  79. ANTONARAKIS ES
    Circulating Tumor Cell Eradication as an Intermediate Efficacy End Point for Metastatic Castration-Resistant Prostate Cancer: Is There Enough Evidence?
    J Clin Oncol. 2017 Dec 22:JCO2017765487. doi: 10.1200/JCO.2017.76.5487.
    PubMed    


  80. HELLER G, McCormack R, Kheoh T, Molina A, et al
    Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
    J Clin Oncol. 2017 Dec 22:JCO2017752998. doi: 10.1200/JCO.2017.75.2998.
    PubMed     Abstract available


  81. ZHU Y, Ye D
    Measurement of Metastasis in the Follow-Up of Localized Prostate Cancer.
    J Clin Oncol. 2017 Dec 21:JCO2017762005. doi: 10.1200/JCO.2017.76.2005.
    PubMed    


  82. HARSHMAN LC, Chen YH, Liu G, Carducci MA, et al
    Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone Sensitive Prostate Cancer Treated With Androgen Deprivation With Or Without Docetaxel.
    J Clin Oncol. 2017 Dec 20:JCO2017753921. doi: 10.1200/JCO.2017.75.3921.
    PubMed     Abstract available


  83. HUSSAIN M, Daignault-Newton S, Twardowski PW, Albany C, et al
    Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
    J Clin Oncol. 2017 Dec 20:JCO2017757310. doi: 10.1200/JCO.2017.75.7310.
    PubMed     Abstract available


  84. PHILLIPS RM, Hayman J, Tran PT
    STOMPing Out Hormone-Sensitive Metastases With Local Therapies in Prostate Cancer.
    J Clin Oncol. 2017 Dec 14:JCO2017765495. doi: 10.1200/JCO.2017.76.5495.
    PubMed    


  85. OST P, Reynders D, Decaestecker K, Fonteyne V, et al
    Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
    J Clin Oncol. 2017 Dec 14:JCO2017754853. doi: 10.1200/JCO.2017.75.4853.
    PubMed     Abstract available


  86. GIRI VN, Knudsen KE, Kelly WK, Abida W, et al
    Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
    J Clin Oncol. 2017 Dec 13:JCO2017741173. doi: 10.1200/JCO.2017.74.1173.
    PubMed     Abstract available


    November 2017
  87. SPRATT DE, Zhang J, Santiago-Jimenez M, Dess RT, et al
    Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.
    J Clin Oncol. 2017 Nov 29:JCO2017742940. doi: 10.1200/JCO.2017.74.2940.
    PubMed     Abstract available


    October 2017
  88. CHEN DY, See LC, Liu JR, Chuang CK, et al
    Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
    J Clin Oncol. 2017 Oct 2:JCO2016714204. doi: 10.1200/JCO.2016.71.4204.
    PubMed     Abstract available


    September 2017
  89. RAJAN P, Sooriakumaran P, Nyberg T, Akre O, et al
    Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study.
    J Clin Oncol. 2017 Sep 20:JCO2016707794. doi: 10.1200/JCO.2016.70.7794.
    PubMed     Abstract available


    August 2017
  90. BAIK SH, Kury FSP, McDonald CJ
    Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.
    J Clin Oncol. 2017 Aug 25:JCO2017726109. doi: 10.1200/JCO.2017.72.6109.
    PubMed     Abstract available


  91. MUCCI LA, Kantoff PW
    Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?
    J Clin Oncol. 2017 Aug 17:JCO2017747915. doi: 10.1200/JCO.2017.74.7915.
    PubMed    


  92. EISENBERGER M, Hardy-Bessard AC, Kim CS, Geczi L, et al
    Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
    J Clin Oncol. 2017 Aug 15:JCO2016721076. doi: 10.1200/JCO.2016.72.1076.
    PubMed     Abstract available


  93. ZHANG T, Armstrong AJ
    The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2017 Aug 15:JCO2017747931. doi: 10.1200/JCO.2017.74.7931.
    PubMed    


  94. LARSEN SB, Dehlendorff C, Skriver C, Dalton SO, et al
    Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer.
    J Clin Oncol. 2017 Aug 14:JCO2016718981. doi: 10.1200/JCO.2016.71.8981.
    PubMed     Abstract available


  95. XIE W, Regan MM, Buyse M, Halabi S, et al
    Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
    J Clin Oncol. 2017 Aug 10:JCO2017739987. doi: 10.1200/JCO.2017.73.9987.
    PubMed     Abstract available


    July 2017
  96. OUDARD S, Fizazi K, Sengelov L, Daugaard G, et al
    Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
    J Clin Oncol. 2017 Jul 28:JCO2016721068. doi: 10.1200/JCO.2016.72.1068.
    PubMed     Abstract available


    June 2017
  97. HARMON SA, Perk T, Lin C, Eickhoff J, et al
    Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone.
    J Clin Oncol. 2017 Jun 27:JCO2017722348. doi: 10.1200/JCO.2017.72.2348.
    PubMed     Abstract available


  98. ANTONARAKIS ES, Tagawa ST, Galletti G, Worroll D, et al
    Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naive, Metastatic, Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2017 Jun 20:JCO2017724138. doi: 10.1200/JCO.2017.72.4138.
    PubMed     Abstract available


  99. BURRIS HA, Infante JR, Ansell SM, Nemunaitis JJ, et al
    Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
    J Clin Oncol. 2017;35:2028-2036.
    PubMed     Abstract available


  100. SPRATT DE, Yousefi K, Deheshi S, Ross AE, et al
    Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.
    J Clin Oncol. 2017;35:1991-1998.
    PubMed     Abstract available


    May 2017
  101. HOFFMAN RM, Lo M, Clark JA, Albertsen PC, et al
    Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study.
    J Clin Oncol. 2017 May 11:JCO2016706317. doi: 10.1200/JCO.2016.70.6317.
    PubMed     Abstract available


  102. PARIKH RR, Kim IY
    Can Genomic Data Guide the Postoperative Management of Prostate Cancer?
    J Clin Oncol. 2017 May 4:JCO2017724849. doi: 10.1200/JCO.2017.72.4849.
    PubMed    


  103. VAN DE WAL M, Thewes B, Gielissen M, Speckens A, et al
    Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial.
    J Clin Oncol. 2017 May 4:JCO2016705301. doi: 10.1200/JCO.2016.70.5301.
    PubMed     Abstract available


  104. LOEB S, Folkvaljon Y, Damber JE, Alukal J, et al
    Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.
    J Clin Oncol. 2017;35:1430-1436.
    PubMed     Abstract available


    April 2017
  105. LECARPENTIER J, Silvestri V, Kuchenbaecker KB, Barrowdale D, et al
    Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
    J Clin Oncol. 2017 Apr 27:JCO2016694935. doi: 10.1200/JCO.2016.69.4935.
    PubMed     Abstract available


  106. VIRGO KS, Basch E, Loblaw DA, Oliver T, et al
    Second-Line Hormonal Therapy for Men With Chemotherapy-Naive, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
    J Clin Oncol. 2017 Apr 25:JCO2017728030. doi: 10.1200/JCO.2017.72.8030.
    PubMed     Abstract available


  107. PERNAR CH, Downer MK, Wilson KM, Stampfer MJ, et al
    Vasectomy and Risk of Prostate Cancer: How to Weigh Current Evidence.
    J Clin Oncol. 2017;35:1272-1273.
    PubMed    


  108. BUBLEY GJ, Balk SP
    Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide.
    J Clin Oncol. 2017 Apr 17:JCO2017728808. doi: 10.1200/JCO.2017.72.8808.
    PubMed    


  109. ANTONARAKIS ES, Lu C, Luber B, Wang H, et al
    Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    J Clin Oncol. 2017 Apr 6:JCO2016701961. doi: 10.1200/JCO.2016.70.1961.
    PubMed     Abstract available


    March 2017
  110. YU JB
    Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales.
    J Clin Oncol. 2017 Mar 29:JCO2017727016. doi: 10.1200/JCO.2017.72.7016.
    PubMed    


  111. ARCANGELI G, Saracino B, Arcangeli S, Gomellini S, et al
    Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial.
    J Clin Oncol. 2017 Mar 29:JCO2016704189. doi: 10.1200/JCO.2016.70.4189.
    PubMed     Abstract available


  112. DALELA D, Santiago-Jimenez M, Yousefi K, Karnes RJ, et al
    Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model.
    J Clin Oncol. 2017 Mar 28:JCO2016699918. doi: 10.1200/JCO.2016.69.9918.
    PubMed     Abstract available


  113. GARZOTTO M
    Is Low-Risk Prostate Cancer More Indolent in Younger Patients?
    J Clin Oncol. 2017 Mar 27:JCO2017723684. doi: 10.1200/JCO.2017.72.3684.
    PubMed    


  114. LEAPMAN MS, Cowan JE, Nguyen HG, Shinohara KK, et al
    Active Surveillance in Younger Men With Prostate Cancer.
    J Clin Oncol. 2017 Mar 27:JCO2016680058. doi: 10.1200/JCO.2016.68.0058.
    PubMed     Abstract available


  115. CHIN J, Rumble RB, Kollmeier M, Heath E, et al
    Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.
    J Clin Oncol. 2017 Mar 27:JCO2016720466. doi: 10.1200/JCO.2016.72.0466.
    PubMed     Abstract available


  116. SMITH BYRNE K, Castano JM, Chirlaque MD, Lilja H, et al
    Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC).
    J Clin Oncol. 2017 Mar 6:JCO2016700062. doi: 10.1200/JCO.2016.70.0062.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: